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Intake of dietary factors that serve as methyl group donors may
influence promoter hypermethylation in colorectal carcinogene-
sis. We investigated whether dietary folate, vitamin B2 and vita-
min B6, methionine and alcohol were associated with mutL
homologue 1 (MLH1) hypermethylation and the related molecu-
lar phenotypes of MLH1 protein expression, microsatellite insta-
bility (MSI) and BRAF mutations in patients with colorectal
carcinomas. Within the Netherlands Cohort Study on diet and
cancer (n 5 120 852), 648 cases (367 men and 281 women) and
4059 subcohort members were available for data analyses from
a follow-up period between 2.3 and 7.3 years after baseline. Gen-
der-specific adjusted incidence rate ratios (RRs) were calculated
over categories of dietary intake in case-cohort analyses. The in-
takes of folate, vitamin B2, methionine and alcohol were not as-
sociated with risk of tumors showing MLH1 hypermethylation,
those lacking MLH1 protein expression or with MSI. Among
men, we observed strong positive associations between folate
and BRAF-mutated tumors (RR 5 3.04 for the highest versus
lowest tertile of intake, Ptrend 5 0.03) and between vitamin B6
and tumors showingMLH1 hypermethylation (highest versus low-
est tertile: RR 5 3.23, Ptrend 5 0.03). Among women, the relative
risks of tumors with BRAFmutations orMLH1 hypermethylation
were also increased in the highest tertiles of folate and vitamin B6
intake, respectively, but these did not reach statistical significance.
The positive associations between folate intake and tumors har-
boring BRAFmutations and between vitamin B6 intake and those
showing MLH1 hypermethylation were most pronounced among
men and may suggest that these vitamins enhance colorectal can-
cer risk through genetic as well as epigenetic aberrations.
Introduction
It has been hypothesized that two forms of genetic instability may
contribute to the carcinogenesis of sporadic colorectal cancer (CRC).
Whereas microsatellite instability (MSI) occurs in 15% of the spo-
radic CRCs, chromosomal instability would account for the remaining
85% (1). Sporadic tumors with MSI present a distinct molecular phe-
notype and may develop predominantly as a consequence of hyper-
methylation of the mismatch repair gene mutL homologue 1 (MLH1)
(2–4). Furthermore, mutations in the BRAF oncogene are strongly
associated with MLH1 promoter methylation and MSI (5) and are an
additional type of molecular alteration characterizing this phenotype.
Dietary factors that serve as methyl group donors, such as folate
and methionine, potentially have an effect at the level of DNA meth-
ylation. A low folate status may decrease genomic DNA methylation,
which in turn presumably contributes to the process of carcinogenesis
(6). A specific form of aberrant methylation that is frequently ob-
served in carcinogenesis involves CpG island promoter hypermethy-
lation of, for example, DNA repair genes (7). It may be hypothesized
that deficient status or low intake of methyl donors could also lead to
increased frequencies of this type of aberrant DNA methylation. In
this respect, in a pilot study (n 5 122 patients), we previously ob-
served a weak association between relatively low folate intake in
combination with high alcohol consumption and increased promoter
hypermethylation of at least one of six of the studied CRC genes (8).
Conversely, it was recently suggested that folate supplementation of
4.6 mg/day in combination with vitamin B12 during 6 months may be
associated with increased levels of promoter hypermethylation in co-
lorectal mucosa, although this association was borderline significant
(9). These results seem contradictive and it is obviously important to
further study the potential effect of relatively high methyl donor in-
take on the occurrence of promoter hypermethylation.
Other dietary factors, such as vitamin B2 and vitamin B6, are also
involved in the folate-mediated one-carbon metabolism (Figure 1).
These vitamins may therefore modulate the bioavailability of methyl
groups and thereby DNA methylation as well (10). Flavin adenine
dinucleotide, a metabolite of vitamin B2, is the cofactor for meth-
ylenetetrahydrofolate reductase (MTHFR), the enzyme that converts
5,10-methylenetetrahydrofolate into 5-methyl-tetrahydrofolate and
thereby enhances DNA methylation. Low vitamin B2 status was
previously observed to be associated with increased tHcy concen-
tration, which possibly results in lower availability of methyl groups
needed for DNA methylation (11). Interestingly, it was suggested
that patients with the MTHFR C677T and A1298C polymorphisms,
which are associated with lower activity of this enzyme, tended to
have a higher level of MLH1 promoter methylation in colon carci-
nomas (12). Subjects with the homozygous MTHFR 677TT variant
also had lower serum folate levels (13) and may be at increased risk
of developing tumors harboring MSI (13,14). Vitamin B6 is involved
in the conversion of tetrahydrofolate into 5,10-methylenetetrahydro-
folate, which is one of the steps of the folate cycle and therefore
essential for the subsequent supply of methyl groups. Conversely,
high alcohol intake reduces the bioavailability of folate and such
a disruption of the one-carbon metabolism may affect DNA meth-
ylation in, for example, the colonic mucosa (15,16). Long-term al-
cohol consumption may also result in an increased risk of tumors
harboring MSI (17,18).
Since folate plays an important role in both DNA synthesis and DNA
methylation, one would expect that adequate folate status or sufficient
folate intake can also reduce the risk of tumors harboring gene muta-
tions. Opposite to this, however, we have previously observed that men
in the third tertile of folate intake may be at increased risk of CRCs with
truncating APC mutations (19). The relation between diet and BRAF
mutations has been studied, but no associations were observed with
folate, vitamin B6, vitamin B12 and methionine (20).
Here, we investigate associations between dietary folate, vitamin
B2, vitamin B6, methionine and alcohol in relation to MLH1 promoter
methylation and the associated molecular characteristics of absence of
MLH1 protein expression, MSI and BRAF mutations in CRCs. This
allows us to establish which of these end points associated with the
MSI phenotype is most sensitive to dietary exposure and whether
the effect of methyl donor intake through folate and methionine
may be modulated by vitamin B2 and vitamin B6 or alcohol. We also
describe the occurrence and overlap between MLH1 promoter meth-
ylation, MLH1 protein expression, MSI and BRAF mutations. This
Abbreviations: CI, confidence interval; CRC, colorectal cancer; FFQ, food fre-
quency questionnaire; MLH1, mutL homologue 1; MSI, microsatellite instability;
MSP, methylation-specific PCR; PALGA, Pathologisch Anatomisch Landelijk
Geautomatiseerd Archief; PCR, polymerase chain reaction; RR, rate ratio.
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study is carried out within the Netherlands Cohort Study on diet and
cancer among a large group of unselected CRC patients.
Subjects and methods
Study population
The participants in this study are incident colon and rectal cancer patients and
subcohort members from the Netherlands Cohort Study, which has been de-
scribed in detail elsewhere (21). Briefly, the study was initiated in 1986 and
includes 58 279 men and 62 573 women aged 55–69 years at baseline, who
originated from 204 Dutch municipalities with computerized population regis-
ters. At baseline, participants completed a self-administered food frequency
questionnaire (FFQ) that also provided information about age, sex and other
risk factors for cancer. The entire cohort was being monitored for cancer
occurrence by annual record linkage to the Netherlands Cancer Registry (nine
cancer registries in the Netherlands) and to PALGA (Pathologisch Anatomisch
Landelijk Geautomatiseerd Archief), a nationwide network and registry of
histopathology and cytopathology reports (22). Accumulation of person-time
in the cohort has been estimated through biennial vital status follow-up of
a subcohort of 5000 men and women who were randomly selected after base-
line exposure measurement. Cases with prevalent cancer other than non-
melanoma skin cancer were excluded from this subcohort, which left 4774
men and women eligible for analysis.
In 1986, the PALGA registry was not implemented in some of the munic-
ipalities included in the study but reached full coverage by the end of 1988.
Incomplete coverage may introduce selection bias, and in addition, possible
preclinical disease may have affected exposure status. For these reasons,
we excluded the first 2.3 years of follow-up from the analyses. A total of
101 subcohort members were either deceased or diagnosed with cancer other
than non-melanoma skin cancer within this period, leaving 4673 men and
women for analysis. From 1989 to 1994, 925 incident cases were identified
with histologically confirmed CRC, of whom 815 could also be linked to
a PALGA report of the lesion. The PALGA database was used to identify
and locate tumor tissue in Dutch pathology laboratories. CRC was classified
according to disease site as follows: colon, i.e. proximal colon (ICD-O-1 codes
153.0, 153.1, 153.4, 153.5, 153.6) and distal colon (153.2, 153.3, 153.7),
rectosigmoid (154.0), rectum (154.1) or ICD-O-1 codes 153.8 and 153.9 if
information of the disease site was not available.
Tissue samples
Tumor material of the CRC patients was collected after approval by the ethical
review boards of Maastricht University, the Netherlands Cancer Registry and
PALGA (23). In addition, all pathology laboratories in the Netherlands agreed
to make relevant tissue samples available from PALGA upon request. Of the
815 tissue samples that were scattered over 54 pathology laboratories in the
Netherlands, 734 samples (90%) could be traced and were retrieved between
August 1999 and December 2001 (23).
MLH1 promoter methylation
DNA methylation in the CpG islands of the MLH1 gene was determined by
chemical modification of genomic DNA with sodium bisulfite and subsequent
methylation-specific polymerase chain reaction (PCR) (MSP, described in de-
tail elsewhere (24)). In brief, 500 ng of DNA was denatured by NaOH and
modified by sodium bisulfite. DNA samples were then purified using Wizard
DNA purification resin (Promega, Leiden, The Netherlands), treated again with
NaOH, precipitated with ethanol and resuspended in H2O.
To facilitate MSP analysis on DNA retrieved from formalin-fixed, paraffin-
embedded tissue, DNA was first amplified with flanking PCR primers (de-
scribed in ref. 8) that amplify bisulfite-modified DNA but do not preferentially
amplify methylated or unmethylated DNA. The resulting fragment was used as
a template for the MSP reaction (8,25).
Fig. 1. The role of folate, vitamin B2, vitamin B6 and alcohol in the synthesis and methylation of DNA. Dietary factors are given in italics. Methyl donors are
folate and methionine; factors that may modulate the bioavailability of methyl groups are vitamin B2, vitamin B6 and alcohol. FAD, flavin adenine dinucleotide;
MTR, methionine synthase; MTRR, methionine synthase reductase.
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All PCRs were performed with controls for unmethylated alleles (DNA from
normal lymphocytes), methylated alleles [normal lymphocyte DNA treated
in vitro with SssI methyltransferase (New England Biolabs, Ipswich, MA)]
and a control without DNA. Ten microliters of each MSP reaction was directly
loaded onto non-denaturing 6% polyacrylamide gels, stained with ethidium
bromide and visualized under UV illumination. MSP analyses of MLH1 were
successfully performed for 686 (93%) of 734 patients. Reproducibility was
high, with duplo analyses performed on a random subset of 72 samples yield-
ing the same result in 89% of the cases.
MLH1 protein expression status
Immunohistochemical analyses were performed and scored on 4 lm sections
of formalin-fixed, paraffin-embedded cancer tissue and adjacent normal tissue
using a monoclonal antibody against MLH1, as previously described (17).
Staining was evaluated with normal cells as internal control. Two investigators
reviewed the immunohistochemical staining profiles independently and dis-
crepancies were re-examined and discussed with a pathologist until consensus
was reached. MLH1 protein expression status was determined successfully in
721 (98%) of the 734 patients.
Microsatellite instability
MSI was determined by a pentaplex PCR using the MSI markers BAT-26, BAT-25,
NR-21, NR-22 and NR-24, as described in detail by Suraweera et al. (26). MSI
analyses were successful on 662 (90%) of the 734 available samples. The re-
producibility was 100% since all the 53 duplo analyses showed identical results.
BRAF mutations
The common V600E BRAF mutation in exon 15 was analyzed by a semi-
nested PCR and subsequent restriction fragment length polymorphism analy-
ses as previously described (27). BRAF mutation status could be analyzed
successfully in 697 (95%) of the 734 tissue samples. The analyses were re-
peated on 33 randomly drawn samples and could be succesfully reproduced in
88% of these cases.
Food frequency questionnaire
The self-administered questionnaire was a 150-item semi-quantitative FFQ,
which concentrated on habitual consumption of food and beverages during
the year preceding the start of the study, and also contained questions about
body weight, body length, smoking status, physical activity and family history
of CRC. Daily mean nutrient intakes were calculated as the cumulated product
of the frequencies and portion sizes of all food items and their tabulated
nutrient contents from the Dutch Food Composition Table (NEVO table,
1986 (28)). The validity and reproducibility of the FFQ were determined
(29,30). Questionnaire data were key entered twice for all incident cases in
the cohort and for all subcohort members in a blinded manner with respect to
case–subcohort status. This was done in order to minimize observer bias in
coding and interpretation of the data.
Folate data were derived from a validated liquid chromatography trienzyme
method (31) used to analyze the 125 most important Dutch foods contributing
to folate intake (32). Mean daily intakes of all other relevant nutrients were
calculated using the computerized Dutch Food Composition Table (28). Di-
etary supplement data were also obtained via the FFQ. However, the use of B
vitamin supplements was low (7%) and folic acid was generally not included in
these supplements in the Netherlands in the late 1980s. Therefore, folic acid
supplement use most probably plays a very minor role in our study population,
and supplement use was not further accounted for in the analyses.
Statistical analyses
The occurrence and relative overlap of MLH1 hypermethylation with any of
the three other characteristics—absence of MLH1 protein expression, MSI and
BRAF mutations—were calculated and tested with Chi-square tests. Dietary
factors and other baseline characteristics were summarized for men and
women separately for subcohort members and CRC cases by calculating means
and standard deviations for continuous variables and distributions of the cat-
egorical variables. Differences in dietary folate, vitamin B2, vitamin B6, me-
thionine and alcohol intake were tested between CRC cases and the cases
without CRC in the subcohort using Student’s t-tests or Chi-square tests where
appropriate. This comparison was also made for the four other molecular
characteristics.
Cox proportional hazards regression models were used to estimate multi-
variate-adjusted incidence rate ratios (RRs) and corresponding 95% confidence
intervals (CIs) over tertiles of folate, vitamin B2, vitamin B6 and methionine
intake and over categories of alcohol intake, using the lowest intake categories
as reference. Standard errors of the RRs were estimated using the robust
Huber–White sandwich estimator to account for additional variance introduced
by sampling from the cohort (33). The proportional hazards assumption was
tested using the scaled Schoenfeld residuals (34). Tests for dose–response
trends over the different categories of intake were estimated by fitting the
ordinal exposure variables as continuous variables and evaluated using the
Wald test. For each end point, a model was used that included all these five
dietary variables. Folate, vitamin B2, vitamin B6 and methionine were adjusted
for total energy intake by calculating nutrient residuals from the regression of
nutrient intake on total energy intake, as described by Willet et al. (35). These
nutrient residuals are uncorrelated with total energy intake, and the effect of the
variation in nutrient intake can subsequently be estimated independently of
a potential effect of energy intake. The RRs were calculated for all colorectal
tumors, for tumors with MLH1 hypermethylation, absence of MLH1 protein
expression, MSI or BRAF mutations. Because tumors presenting MSI usually
occur more frequently among women and may have a different etiology than in
men, we have chosen to present gender-specific results. In addition to these
analyses, we also performed overall analyses for men and women combined in
order to create larger subgroups and thereby to reduce the probability of
reporting chance findings.
Tests for heterogeneity were performed to evaluate differences between
subtypes of tumors (e.g. MLH1 methylated versus unmethylated) using the
competing risks procedure in Stata. However, the standard error for the differ-
ence of the log Hazard Ratios from this procedure assumes independence of
both estimated Hazard Ratios, which would underestimate that standard error
and thus overestimate the P values for their difference. Therefore, these P
values and the associated CIs were estimated based on a bootstrapping method
that was developed for the case-cohort design (36). For each bootstrap sample,
X subcohort members were randomly drawn from the subcohort of X subjects
and Y cases from the total of Y cases outside the subcohort, both with replace-
ment, out of the dataset of Xþ Yobservations. The log HRs were obtained from
this sample using Stata’s competing risks procedure and recalculated for each
bootstrap replication. The CI and P value of the differences in hazard ratio of
the subtypes were then calculated from the replicated statistics. Each bootstrap
analysis was based on 1000 replications.
The covariates included in the multivariate analyses were those found to
influence the RR by .10% or those observed to be associated with CRC in
previous studies. This applied for the variables age, family history of CRC,
smoking, body mass index and dietary intakes of energy, meat, fat, fiber,
vitamin C, iron and calcium. After excluding subjects with missing informa-
tion on these covariates or subjects who only partly filled out the questionnaire,
4059 subcohort members remained for statistical analyses as well as 648 CRC
cases, irrespective of the available molecular analyses.
We determined possible interactions between dietary intakes of methyl do-
nors (folate and methionine) and the potentially ‘modulating’ factors vitamin
B2, vitamin B6 and alcohol for each of the individual end points. This was
done by first testing, in separate models, the gender-specific interaction terms
between folate and methionine with vitamin B2, vitamin B6 and alcohol, i.e.
folate  methionine, folate B2, folate B6, folate alcohol, methionine B2,
methionine  B6 and methionine  alcohol. The Cox proportional hazard
analyses without the interaction terms were subsequently stratified by low or
high intake of folate, vitamin B2, vitamin B6 and methionine using the median
intakes as cutoff values to define both strata within each variable. The strata
used for alcohol intake were 1, abstainers; 2, subjects with intake ,30 g/day
and 3, subjects who consumed 30 g/day.
All statistical analyses were performed with the Stata statistical software
package (version 9.1).
Results
Among the CRC patients in our study, we first assessed the occurrence
of MLH1 hypermethylation, MLH1 protein expression, MSI and
BRAF mutations. The analyses of these four characteristics were
complete in 648 patients. The frequencies and percentages as well
as the overlap between these molecular phenotypes are shown in
Table I and Figure 2. In 152 (22.1%) of the patients with successful
MLH1 MSP analyses, promoter methylation of this gene was found.
The percentages of tumors that lacked the MLH1 protein, those with
MSI as determined by the MSI pentaplex assay or those harboring
BRAF mutations were 8.5, 12.7 and 16.1%, respectively. Although the
associations between MLH1 hypermethylation and the three other
aberrations individually were highly significant (all Chi-square tests
had P , 0.001), the overlap between the four molecular phenotypes,
which was based on patients with all molecular analyses available,
was not complete. The highest relative overlap was observed with
MLH1 protein expression since of the 55 tumors lacking the MLH1
protein, 41 (74.6%) also showed MLH1 hypermethylation. The over-
lap between MSI and MLH1 hypermethylation was lower, with
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50 (65.8%) of 76 tumors harboring MSI also having MLH1 hyper-
methylation. The lowest percentage of overlap was observed between
BRAF mutations and MLH1 hypermethylation, as 48 (47.5%) of 101
BRAF-mutated tumors had a hypermethylated MLH1 gene.
We then explored dietary intakes and other baseline characteristics
of subcohort members and cancer cases with MLH1 promoter meth-
ylation, absence of MLH1 protein expression, MSI or BRAF muta-
tions among men and women (Table II). The percentage of male
patients with a family history of CRC was substantially lower among
men with a hypermethylated MLH1 gene compared with all CRC
tumors combined in men. It was also clear that tumors with MLH1
hypermethylation, without MLH1 protein expression, with MSI or
with BRAF mutations all occurred more often in the proximal colon
when compared with the total group of tumors in both men and
women. The intakes of folate, vitamin B2, vitamin B6, methionine
and alcohol were similar among cases in the different subgroups
compared with subcohort members.
We subsequently estimated the associations between intakes of
folate, vitamin B2, vitamin B6, methionine and alcohol on the one
hand, with colorectal carcinoma risk with or without MLH1 hyper-
methylation, absence of MLH1 protein expression, MSI or BRAF
mutations on the other hand. Among men, folate intake was not as-
sociated with overall CRC, with tumors showing MLH1 hypermethy-
lation, lacking MLH1 protein expression or with MSI. However, it
was positively associated with colorectal tumors harboring BRAF
mutations in men (RR 5 3.04, CI 5 1.13–8.20, Ptrend 5 0.03 for
the highest versus the lowest tertile of intake, Table III). Conversely,
there was an inverse association between methionine intake and risk
of BRAF-mutated tumors (highest versus lowest tertile: RR 5 0.28,
CI 5 0.09–0.86, Ptrend 5 0.02). Both vitamin B2 and alcohol were not
associated with any of the end points studied in men. However, dietary
intake of vitamin B6 was positively associated with overall CRC in
men (RR 5 1.54, CI 5 1.01–2.36, Ptrend 5 0.06 for the highest versus
the lowest tertile of intake). The association between vitamin B6 and
tumors with MLH1 hypermethylation in men was even stronger (RR 5
3.23, CI 5 1.15–9.06, Ptrend 5 0.03).
Among women, dietary intakes of folate, vitamin B2, vitamin B6,
methionine and alcohol were not associated with overall CRC or any
of the end points studied (Table IV). Although the RRs of tumors with
BRAF mutations and those with MLH1 hypermethylation were also
increased in the highest tertiles of folate and vitamin B6 intake, re-
spectively, these associations were not statistically significant among
women.
Increased relative risks could be observed in the highest category of
alcohol intake for most of the end points; however, trends were not
statistically significant and the numbers of cases in the highest cate-
gory were low for both men and women.
When performing overall analyses for men and women together
(data not shown), we observed that, although borderline significant,
the highest tertile of folate intake was associated with colorectal tumors
harboring BRAF mutations (RR 5 1.85, CI 5 0.92–3.73, Ptrend 5
0.08). There clearly were positive associations between vitamin B6
intake and overall CRC (RR 5 1.51, CI 5 1.11–2.04, Ptrend 5 0.01)
and risk of tumors with MLH1 promoter methylation (RR 5 2.32,
Table I. Frequencies of molecular phenotypes and overlap of MLH1










Methylated 152 (22.1) — — —
Unmethylated 534 (77.9) — —
MLH1 expression
No 61 (8.5) 41 (74.6) 14 (25.4) ,0.001
Yes 660 (91.5) 97 (17.3) 463 (82.7)
MSI
Present 84 (12.7) 50 (65.8) 26 (34.2) ,0.001
Absent 578 (87.3) 88 (16.3) 452 (83.7)
BRAF
Mutation 112 (16.1) 48 (47.5) 53 (52.5) ,0.001
Wild-type 585 (83.9) 90 (17.5) 425 (82.5)
aNumbers and percentages are based on tumors with complete analyses of all
four molecular characteristics (tumors of 648 cases in total).
MLH1 hypermethylation (n=125)















Fig. 2. Overlap between MLH1 hypermethylation, absence of MLH1 protein expression, MSI and BRAF mutations in tumors showing at least one of these four
aberrations. In total, there were 238 tumors harboring at least one aberration. Numbers are based on tumors with complete analyses of all four molecular
characteristics (tumors of 648 cases in total). The sizes of the different areas in this figure do not exactly reflect the numbers of the applicable subsets.
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Table II. Baseline dietary intake (mean ± SD) and other characteristics of cancer cases and subcohort members from the Netherlands Cohort Study on diet and cancer
Men Women













na 2017 367 65 24 38 49 2042 281 73 32 38 52
Age (years) 61.3 ± 4.2 62.7 ± 4.1 62.5 ± 4.1 63.4 ± 4.4 62.9 ± 4.6 62.1 ± 4.2 61.3 ± 4.3 62.9 ± 3.9 62.5 ± 4.4 62.7 ± 4.6 63.6 ± 4.3 62.9 ± 4.0
Family history
of CRC (% yes)
5.5 12.0 4.6 9.4 7.9 8.2 5.9 10.0 9.6 9.4 7.9 11.5
Tumor sublocalization (%)
Proximal — 29.0 52.4 83.3 73.7 62.5 — 39.9 57.8 84.4 89.2 68.6
Distal — 33.2 22.2 8.3 18.4 14.6 — 30.2 25.4 15.6 10.8 19.6
Rectosigmoid — 10.5 9.5 8.3 7.9 2.1 — 11.5 7.0 0 0 2.0
Rectum — 27.3 15.9 0 0 20.8 — 18.4 9.8 0 0 9.8
Body mass
index (kg/m2)
25.0 ± 2.6 25.4 ± 2.7 25.6 ± 2.5 25.7 ± 2.5 25.3 ± 2.3 25.2 ± 2.4 25.0 ± 3.6 25.6 ± 3.6 25.2 ± 3.4 25.5 ± 4.0 25.9 ± 4.2 25.6 ± 3.5
Smoking status (%)
Never 12.9 9.8 7.7 4.2 7.9 14.3 57.6 61.6 61.6 53.1 55.3 55.8
Ex-smoker 51.7 63.2 61.5 50.0 60.5 53.1 20.8 22.4 21.9 25.0 18.4 32.7
Current smoker 35.4 27.0 30.8 45.8 31.6 32.6 21.6 16.0 16.4 21.9 26.3 11.5
Dietary factors
Energy (kJ/day) 9091 ± 21.37 8909 ± 1866 8911 ± 1715 8674 ± 1412 9211 ± 1863 8969 ± 1410 7062 ± 1655 6997 ± 1695 6774 ± 1741 6685 ± 1381 6851 ± 1516 6675 ± 1373
Folate (lg/day) 225.0 ± 75.3 225.5 ± 75.4 225.0 ± 73.9 209.5 ± 50.3 228.4 ± 89.1 233.5 ± 81.3 198.8 ± 67.6 197.6 ± 70.5 187.1 ± 64.5 198.4 ±101.9 191.8 ± 97.3 190.8 ±81.9
Vitamin B2 (mg/day) 1.58 ± 0.37 1.57 ± 0.35 1.62 ± 0.38 1.70 ± 0.38 1.65 ± 0.39 1.59 ± 0.36 1.45 ± 0.35 1.44 ± 0.34 1.37 ± 0.31 1.42 ± 0.35 1.38 ± 0.33 1.39 ± 0.31
Vitamin B6 (mg/day) 1.54 ± 0.27 1.56 ± 0.27 1.58 ± 0.28 1.56 ± 0.22 1.52 ± 0.26 1.56 ± 0.25 1.33 ± 0.24 1.34 ± 0.23 1.31 ± 0.22 1.33 ± 0.31 1.32 ± 0.31 1.33 ± 0.27
Methionine (mg/day) 1713 ± 293 1701 ± 284 1693 ± 274 1729 ± 252 1676 ± 266.2 1699 ± 2.68 1491 ± 276 1492 ± 271 1436 ± 254 1451 ± 263 1452 ± 261 1487 ± 243
Alcohol (%)
0 g/day 14.3 13.4 12.3 25 15.8 10.2 32.3 36.7 31.5 34.4 34.2 36.5
,30 g/day 71.2 69.2 72.3 66.7 73.7 75.5 64.3 58.7 61.6 56.2 57.9 55.8
30 g/day 14.6 17.4 15.4 8.3 10.5 14.3 3.4 4.6 6.9 9.4 7.9 7.7
Meat (g/day) 137.3 ± 52.2 132.2 ± 47.3 132.1 ± 45.6 128.5 ± 41.6 125.0 ± 42.5 135.1 ± 44.4 116.1 ± 46.0 118.2 ± 42.8 113.0 ± 43.3 116 ± 42.5 117.3 ± 40.5 116.6 ± 48.1
Fat (g/day) 94.0 ± 14.2 93.5 ± 12.8 96.8 ± 12.0 99.0 ± 12.0 95.0 ± 11.7 95.3 ± 10.3 74.0 ± 10.3 74.9 ± 10.5 74.8 ± 10.6 73.2 ± 11.9 74.8 ± 12.5 74.1 ± 11.6
Fiber (g/day) 28.7 ± 7.3 29.6 ± 6.7 29.4 ± 7.0 28.6 ± 5.9 28.8 ± 8.0 29.2 ± 7.3 25.3 ± 5.8 24.8 ± 5.6 25.4 ± 6.5 24.9 ± 6.8 24.7 ± 7.2 24.6 ± 5.8
Vitamin C (mg/day) 98.8 ± 41.6 106.8 ± 44.9 102.6 ± 45.9 95.2 ± 30.2 95.8 ± 42.5 105.4 ± 46.3 108.4 ± 42.7 107.0 ± 43.2 102.6 ± 45.0 103.7 ± 47.0 99.0 ± 42.4 102.0 ± 44.2
Iron (mg/day) 13.2 ± 2.4 13.7 ± 2.4 13.6 ± 2.5 13.4 ± 1.7 13.4 ± 2.3 13.7 ± 2.6 11.7 ± 2.0 11.6 ± 2.0 11.6 ± 1.9 11.6 ± 1.9 11.5 ± 2.0 11.7 ± 1.6
Calcium (mg/day) 947 ± 293 943 ± 281 964 ± 279 1048 ± 364 1006 ± 344 950 ± 306 903 ± 268 899 ± 256 839 ± 216 860 ± 243 863 ± 245 858 ± 233













































aastricht user on 23 Septem
ber 2021
CI 5 1.21–4.43, Ptrend 5 0.01). The tests for heterogeneity did not
show significant differences between tumors with or without MLH1
hypermethylation, MLH1 protein expression, MSI or BRAF muta-
tions (data not shown).
After testing potential interactions, it appeared that there was no
interaction between folate and methionine, vitamin B2 or alcohol in
either men or women. However, among men, we observed an inter-
action between folate and vitamin B6 for overall CRC. In this respect,
stratified analyses revealed that relatively high vitamin B6 intake was
associated with an increased risk of overall CRC among men who had
a folate intake in the category above the median (RR 5 1.96, CI 5
1.06–3.60, Ptrend 5 0.02 for the highest versus the lowest tertile of
B6 intake, data not shown), whereas the RR was not increased among
subjects with folate intake below the median of the distribution
(Pinteraction 5 0.06). Similarly, men having tumors with MLH1 hyper-
methylation also had higher RRs in the third tertile of vitamin B6
intake in the subgroup of high folate intake (RR 5 3.36, CI 5 0.81–
13.93, Ptrend 5 0.08, data not shown), which was not observed among
men with low folate intake. However, the interaction term for this end
point was not statistically significant. Among women, an interaction
between vitamin B6 and folate was not observed, though it was pres-
ent for men and women combined for overall CRC (Pinteraction 5
0.07). We observed no interactions between methionine and any of
the other dietary variables under study.
Discussion
In this study, we investigated the associations between dietary folate,
vitamin B2, vitamin B6, methionine, alcohol and CRC risk while
accounting for MLH1 promoter methylation, MLH1 protein expres-
sion, MSI and BRAF mutations. It was observed that the highest
tertiles of folate, vitamin B2, vitamin B6 and methionine intake and
low alcohol intake were not associated with decreased CRC risk,
irrespective of the presence of MLH1 hypermethylation, the MLH1
protein or MSI. On the other hand, we observed a positive association
between dietary folate and BRAF mutations in men. Moreover, vita-
min B6 increased overall CRC risk and especially MLH1 hyperme-
thylated tumors among men.
We studied four different aberrations that have been suggested pre-
viously to be associated with the MSI pathway. Despite the strong and
statistically significant correlations between these characteristics, they
were not always concurrently present in tumors. Whereas the percen-
tages of overlap between absence of MLH1 protein expression and
MLH1 methylation and between MSI and MLH1 methylation were
relatively high (74.6 and 65.8%, respectively), less than half of the
tumors with BRAF mutations (47.5%) appeared to have MLH1 meth-
ylation. In this respect, it is appreciated that individual techniques
were used for each end point, each having specific sensitivities, which
may partly account for the observed incomplete overlap. However, an
additional, even more obvious, reason may lie in potential differences
in tumor biology. For example, within the subset of sporadic CRCs
showing MSI, there may be differences in the frequency of MLH1
hypermethylation depending on the localization of the tumor. In this
respect, MLH1 hypermethylation was observed less frequently in dis-
tal sporadic CRCs with MSI compared with proximal MSI cancers,
suggesting that an epigenetic pathway has played a smaller role in the
development of distal MSI cancers (37). Next to MLH1 hypermethy-
lation, MLH1 mutations may result in loss of the MLH1 protein as
well. Although such mutations are mainly observed in tumors of
hereditary non-polyposis colorectal cancer patients with MSI (38),
it has been suggested that they may also occur in sporadic colorectal
carcinomas and that MSI may be present concurrently (39). The oc-
currence of MLH1 hypermethylation, lack of MLH1 protein expres-
sion or BRAF mutations may apparently differ among tumors that
develop through the MSI pathway. In addition to the observed in-
complete overlap in our study, this is an important reason to study




PYa Overall MLH1 hypermethylation No MLH1 protein MSI BRAF mutations
nb RRc 95% CI n RR 95% CI n RR 95% CI n RR 95% CI n RR 95% CI
Folate (lg/day)
1 (163.2) 3207 125 1.00 24 1.00 8 1.00 13 1.00 10 1.00
2 (211.6) 3248 110 0.79 0.57–1.08 18 0.66 0.31–1.40 10 1.42 0.51–3.99 14 1.02 0.42–2.51 19 2.33 1.07–5.06
3 (279.9) 3258 132 0.97 0.65–1.44 23 0.88 0.36–2.14 6 1.00 0.20–5.10 11 0.78 0.23–2.67 20 3.04 1.13–8.20
P value for linear trend 0.88 0.83 0.95 0.66 0.03
Vitamin B2 (mg/day)
1 (1.26) 3282 126 1.00 20 1.00 6 1.00 11 1.00 16 1.00
2 (1.53) 3259 128 0.95 0.70–1.31 24 1.19 0.56–2.55 8 1.15 0.35–3.75 11 1.04 0.42–2.57 16 0.80 0.36–1.76
3 (1.90) 3172 113 0.80 0.53–1.21 21 0.93 0.35–2.46 10 1.13 0.24–5.31 16 1.59 0.56–4.53 17 0.79 0.28–2.24
P value for linear trend 0.32 0.92 0.88 0.39 0.67
Vitamin B6 (mg/day)
1 (1.29) 3242 104 1.00 15 1.00 7 1.00 14 1.00 16 1.00
2 (1.53) 3258 128 1.32 0.94–1.85 25 2.26 1.02–5.04 8 1.53 0.47–4.99 11 1.09 0.42–2.81 16 0.94 0.42–2.09
3 (1.79) 3212 135 1.54 1.01–2.36 25 3.23 1.15–9.06 9 2.49 0.57–10.86 13 1.82 0.57–5.80 17 1.04 0.35–3.08
P value for linear trend 0.06 0.03 0.24 0.31 0.89
Methionine (mg/day)
1 (1445) 3243 127 1.00 26 1.00 8 1.00 15 1.00 19 1.00
2 (1697) 3290 127 0.98 0.69–1.40 18 0.46 0.22–0.99 8 0.51 0.16–1.56 13 0.65 0.26–1.64 17 0.60 0.27–1.34
3 (1986) 3180 113 0.93 0.56–1.52 21 0.42 0.14–1.25 8 0.25 0.03–1.90 10 0.35 0.07–1.83 13 0.28 0.09–0.86
P value for linear trend 0.77 0.12 0.17 0.20 0.02
Alcohol
0 g/day (0) 1370 49 1.00 8 1.00 6 1.00 6 1.00 5 1.00
,30 g/day (6.7) 6907 254 1.05 0.74–1.50 47 1.14 0.54–2.41 16 0.60 0.19–1.88 28 1.02 0.39–2.67 37 1.52 0.57–4.05
30 g/day (40.6) 1437 64 1.25 0.78–2.00 10 1.61 0.61–4.21 2 0.54 0.09–3.17 4 0.74 0.19–2.89 7 1.40 0.39–4.94
P value for linear trend 0.36 0.36 0.42 0.68 0.57
aNumber of accumulated person-years (PY) within categories of dietary intake.
bNumber of cases within categories of dietary intake.
cIncidence RR from a Cox regression model including the variables folate, vitamin B2, vitamin B6, methionine and alcohol. Adjusted for age, family history of
CRC, smoking behavior, body mass index, energy, meat, total fat, fiber, vitamin C, total iron and calcium.
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these molecular phenotypes separately in relation to methyl donor
intake. From our results, it appeared that the end point of MSI is least
related to the intake of the studied methyl donors but that there rather
may be an effect on methylation and mutations that are associated
with MSI. Moreover, the relation between folate intake and MSI in
CRC was investigated previously (18), but no association was ob-
served in that particular study.
Promoter hypermethylation and global hypomethylation are alter-
native types of aberrant methylation, and it has been suggested that
both these patterns may contribute separately to the process of co-
lorectal carcinogenesis (40,41). Moreover, they may also specifically
affect DNA stability, given the observed strong associations between
promoter hypermethylation and MSI and between global hypomethy-
lation and chromosomal instability in colorectal carcinomas (42,43).
However, the relative contribution of methyl donor intake to either
hypermethylation or hypomethylation is unknown. Promoter hyper-
methylation may occur in normal colorectal mucosa of patients with
hyperplastic polyposis (44) or CRC (45), suggesting that dietary
methyl donors may play a role in the prevention or initiation of neo-
plastic formation. Moreover, folic acid supplementation may decrease
global hypomethylation in the normal-appearing colonic mucosa of
patients with adenomas (46). Furthermore, in a pilot study, we pre-
viously observed an indication for an inverse association between
relatively high folate intake in combination with low alcohol intake
and promoter methylation in colorectal tumors (8). However, this
association was only weak, and the conclusion in this study was based
on an outcome measure defined as hypermethylation of at least one of
six genes. Others observed positive associations between high alcohol
consumption and risk of MSI-H tumors (17,18,20), indicating that
disruption of the folate metabolism may lead to CRC, possibly partly
through increasing promoter hypermethylation.
Although the above suggests a protective effect of adequate folate
status or intake on aberrant methylation, it has been hypothesized that
its actual influence may also differ depending on the stage of tumor
development in colorectal carcinogenesis. Although folate deficiency
might increase the risk of neoplastic transformation of normal tissue
by inducing genomic hypomethylation, it may have an inhibitory
effect on progression of neoplasms to cancer. Conversely, folate sup-
plementation may prevent aberrant DNA methylation in normal tissue
but could promote established lesions by increasing promoter hyper-
methylation (47). Results of a recent study suggest that folic acid and
vitamin B12 supplementation in subjects with a history of colorectal
adenoma may indeed increase promoter hypermethylation, although
this association was statistically borderline significant (9). Moreover,
folic acid supplementation was associated with increased risk of ad-
vanced lesions or recurrence of multiple adenomas in patients with
available follow-up information (48). Interestingly, the participants in
that study also had a recent history of colorectal adenomas, and pos-
sibly, undetected neoplasms were present in these subjects, which
may have had a growth advantage in the presence of high concen-
trations of folic acid. However, one might wonder whether intake of
dietary folate has a similar effect as supplementation with folic acid.
Nevertheless, our data revealed the strongest increased risk among
patients in the highest tertile of vitamin B6 intake of tumors with
MLH1 hypermethylation, suggesting that vitamin B6 may have had
a tumor-promoting effect by increasing promoter methylation. We
also observed that the increased RRs in the highest tertiles of vitamin
B6 of overall CRC and tumors harboring MLH1 hypermethylation
were present only among men who also had a relatively high folate
intake. The latter association suggests that the transfer of methyl
donors provided by folate may at least partly depend on the availabil-
ity of vitamin B6 as a ‘modulating’ factor and that the combination
of relatively high vitamin B6 and folate intake may increase promoter
methylation and thereby enhance the development of tumors with
a methylation-associated phenotype. Our results therefore contribute
to the hypothesis that relatively high methyl donor intake poten-
tially increases aberrant promoter hypermethylation rather than pre-
venting it.




PYa Overall MLH1 hypermethylation No MLH1 protein MSI BRAF mutations
nb RRc 95% CI § N RR 95% CI N RR 95% CI N RR 95% CI N RR 95% CI
Folate (lg/day)
1 (142.4) 3295 98 1.00 31 1.00 12 1.00 16 1.00 20 1.00
2 (186.6) 3384 99 1.02 0.72–1.47 22 0.79 0.39–1.58 11 1.27 0.50–3.19 13 0.93 0.37–2.34 17 1.23 0.58–2.61
3 (247.9) 3359 84 0.92 0.57–1.48 20 0.88 0.33–2.32 9 1.22 0.31–4.74 9 0.72 0.19–2.72 15 1.42 0.51–3.95
P value for linear trend 0.76 0.76 0.68 0.67 0.47
Vitamin B2 (mg/day)
1 (1.12) 3324 97 1.00 32 1.00 14 1.00 16 1.00 22 1.00
2 (1.42) 3358 90 0.99 0.69–1.41 22 0.84 0.45–1.56 7 0.66 0.22–1.99 10 0.85 0.34–2.13 14 0.75 0.33–1.71
3 (1.76) 3356 94 1.08 0.68–1.71 19 0.94 0.39–2.26 11 1.18 0.31–4.48 12 1.26 0.37–4.23 16 0.93 0.30–2.91
P value for linear trend 0.95 0.78 0.94 0.92 0.68
Vitamin B6 (mg/day)
1 (1.12) 3330 90 1.00 23 1.00 13 1.00 15 1.00 21 1.00
2 (1.32) 3416 92 1.16 0.80–1.69 26 1.39 0.70–2.75 7 0.57 0.17–1.86 10 0.78 0.28–2.18 12 0.56 0.23–1.34
3 (1.54) 3292 99 1.45 0.93–2.28 24 1.61 0.70–3.71 12 0.93 0.29–3.01 13 1.10 0.36–3.39 19 0.97 0.39–2.46
P value for linear trend 0.11 0.27 0.88 0.89 0.96
Methionine (mg/day)
1 (1232) 3370 96 1.00 28 1.00 13 1.00 15 1.00 17 1.00
2 (1476) 3331 85 0.83 0.56–1.22 25 1.08 0.51–2.30 7 0.69 0.21–2.30 9 0.69 0.24–2.00 16 1.44 0.59–3.49
3 (1738) 3338 100 0.89 0.53–1.51 20 1.13 0.39–2.29 12 1.19 0.34–4.13 14 1.15 0.33–4.01 19 2.06 0.67–6.32
P value for linear trend 0.64 0.83 0.89 0.88 0.23
Alcohol
0 g/day (0) 3210 103 1.00 23 1.00 11 1.00 13 1.00 19 1.00
,30 g/day (3.9) 6478 165 0.82 0.62–1.10 45 1.10 0.62–1.94 18 0.93 0.41–2.11 22 1.02 0.48–2.17 29 0.77 0.41–1.47
30 g/day (36.8) 351 13 1.58 0.78–3.20 5 3.81 1.27–11.47 3 3.38 0.97–11.87 3 3.96 1.09–4.40 4 2.54 0.70–9.19
P value for linear trend 0.54 0.29 0.64 0.53 0.99
aNumber of accumulated person-years (PY) within categories of dietary intake.
bNumber of cases within categories of dietary intake.
cIncidence RR from a Cox regression model including the variables folate, vitamin B2, vitamin B6, methionine and alcohol. Adjusted for age, family history of
CRC, smoking behavior, body mass index, energy, meat, total fat, fiber, vitamin C, total iron and calcium.
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Several other studies showed inverse associations between vitamin
B6 intake and CRC risk. However, in these studies, the levels of vitamin
B6 intake were generally higher and the distributions sometimes even
lie largely above the median intake of the highest tertile of the Dutch
population included in our study (49–52). One could hypothesize that if
vitamin B6 is protective above a certain threshold of intake, this may
have been a reason why we did not observe an inverse association.
However, vitamin B6 was also associated with decreased CRC risk
in a recent study in a Japanese population, in which intake of vitamin
B6 was comparable with that in our study (53). There is one study that
has previously demonstrated a positive association between vitamin B6
intake and CRC risk among women who had a much higher vitamin B6
intake than in our study population (54). Apparently, a potential posi-
tive association between vitamin B6 and CRC should be taken into
account and obviously needs further attention in future studies.
Another interesting finding in our study is the positive association
between dietary folate and BRAF mutations among men, which was
not expected considering the importance of folate for nucleotide syn-
thesis. We have previously observed that folate may increase the risk
of tumors harboring truncating APC mutations in men (19). BRAF and
APC mutations are inversely correlated in this study population,
which was also the case in a previous study (55), indicating that
relatively high folate intake may give a growth advantage to mutated
tumors independent of the type of mutation. Moreover, folate was not
associated with MLH1 hypermethylation in men, suggesting that it
exerts a specific effect on tumors with gene mutations.
A limitation of our study is that some of the molecular subgroups
present relatively small numbers of cases, and the possibility that
some of the gender-specific results are partly based on chance can
therefore not be excluded. However, overall analyses, with subgroups
then containing substantial numbers of cases (at least 30) within ter-
tiles of intake, showed similar positive associations of folate with
BRAF mutations and of vitamin B6 with MLH1 hypermethylation.
Furthermore, residual confounding may have been present for the
associations observed, although methyl donor intake was comparable
between molecular subgroups and associations were further adjusted
for a number of potential confounders or known risk factors of CRC.
We consider it unlikely that changes in dietary intake over time have
influenced disease outcome since the reproducibility of the baseline
FFQ over a period of 5 years was relatively high (30) and the follow-
up of 7.3 years was only 2.3 years longer in the current study.
In this Dutch population, relatively high intakes of folate, vitamin
B2, vitamin B6 and methionine or low alcohol intake were not asso-
ciated with a decreased risk of CRC or with tumors harboring MLH1
hypermethylation, lack of MLH1 protein expression or MSI. The
occurrence of MSI does not seem to be sensitive to methyl donor
intake; however, folate increased the risk of BRAF mutations, whereas
vitamin B6 increased the risk of tumors with MLH1 hypermethylation
among men. This may indicate that dietary folate and vitamin B6 have
different effects but may both enhance colorectal carcinogenesis by
exerting an effect on genetic or epigenetic alterations.
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